A strategy for platelet transfusion in patients with alloantibodies to platelets

Abstract

SUMMARY Although antibody‐dependent platelet transfusion refractoriness has become less frequent with the introduction of leukocyte filtration of platelet concentrates, it remains a challenge in transfusion medicine. Small transfusion centers do not have easy access to an inventory of human leukocyte antigen (HLA)‐typed platelet donors. As flow cytometry has become more common, this technology can easily be introduced in platelet crossmatching, with sensitivity and predictive values comparable to those of other techniques, and with the advantage of automation. An algorithm is presented for use of flow cytometry in the selection of compatible platelets for alloimmunized patients.

Good Manufacturing Practice‐Grade of Megakaryocytes Produced by a Novel Ex Vivo Culturing Platform

“…Thus, it is imperative that alternative strategies need to be developed for obtaining donor-independent platelets for clinical uses. 5,6 Ex vivo (EV) production of megakaryocytes (MKs) and platelets has been successfully achieved from various stem origins, including hematopoietic stem cells (HSCs), small-molecule/cytokine cocktail pre-expanded hematopoietic stem cells. In addition, the optimal storage condition for the MKs was defined as normal saline with 10% human serum albumin at 22℃.…”

“…Besides, there are some distinct disadvantages in donor‐derived platelets including the short‐life span, potential refractoriness to repeated transfusions, and a risk of potential viral or bacterial contaminations. Thus, it is imperative that alternative strategies need to be developed for obtaining donor‐independent platelets for clinical uses 5,6 …”

Editorial: the art of platelet transfusion

“…Skogen and Husebekk 7 address the challenge of efficient transfusion therapy in patients with alloantibodies to platelet antigens. These antibodies can be directed toward AB blood type antigens, human leukemia antigens (HLA) or human platelet antigens (HPA).…”